^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Vanflyta (quizartinib) (FLT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Excerpt:
    ...- Patients are eligible regardless of their FLT3 mutation status....
    Trial ID:
    NCI-2018-01813
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY

    Published date:
    05/12/2022
    Excerpt:
    Treatment with Gilteritinib and Quizartinib as monotherapy is an effective and tolerable option for patients with R/R FLT3-mutated AML in real-life, with similar response rates…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Chemother Pharmacol
    Title:

    Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia

    Published date:
    08/03/2020
    Excerpt:
    Overall survival was predicted to be significantly better with quizartinib 200 mg administered every 48 h vs every 24 h in patients with FLT3 aberrations.
    DOI:
    10.1007/s00280-020-04114-z
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASH 2020
    Title:

    Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

    Published date:
    11/04/2020
    Excerpt:
    In the FLT3 positive AML cohort, six patients were registered and one achieved remission by quizartinib after progression on gilteritinib.
    DOI:
    https://doi.org/10.1182/blood-2020-139147